Author
Alan R. Zinsmeister
Other affiliations: University of Rochester, University of Southern California, NewYork–Presbyterian Hospital ...read more
Bio: Alan R. Zinsmeister is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Population & Gastric emptying. The author has an hindex of 118, co-authored 542 publications receiving 52909 citations. Previous affiliations of Alan R. Zinsmeister include University of Rochester & University of Southern California.
Papers published on a yearly basis
Papers
More filters
TL;DR: Symptoms of reflux are common among white men and women who are 25-74 years of age and heartburn and acid regurgitation are significantly associated with chest pain, dysphagia, dyspepsia, and globus sensation.
2,034 citations
TL;DR: At 1 year, 32% of patients with Crohn's disease and 48% with ulcerative colitis are corticosteroid free without operation.
1,068 citations
TL;DR: Immunosuppressive medications, especially when used in combination, and older age are associated with increased risk of opportunistic infections in inflammatory bowel disease patients.
946 citations
TL;DR: F Fistulas in Crohn's disease were common in the community, and in contrast to referral-based studies, only 34% of patients developed recurrent fistulas.
939 citations
TL;DR: Subcutaneous etanercept at a dose of 25 mg twice weekly is safe, but not effective, for the treatment of patients with moderate to severe Crohn's disease.
918 citations
Cited by
More filters
TL;DR: Employing a consensus approach, the working team critically considered the available evidence and multinational expert criticism, revised the Rome II diagnostic criteria for the functional bowel disorders, and updated diagnosis and treatment recommendations.
4,302 citations
TL;DR: Although there are few epidemiologic data from developing countries, the incidence and prevalence of IBD are increasing with time and in different regions around the world, indicating its emergence as a global disease.
4,096 citations
McGill University1, New York University2, Mayo Clinic3, French Institute of Health and Medical Research4, Federal Institute for Drugs and Medical Devices5, University of New South Wales6, Rush University Medical Center7, University of California, Los Angeles8, Vancouver Hospital and Health Sciences Centre9, University of Pittsburgh10, Ludwig Maximilian University of Munich11, VU University Medical Center12, Women's College, Kolkata13, Case Western Reserve University14, Karolinska Institutet15
TL;DR: Mild cognitive impairment can be regarded as a risk state for dementia, and its identification could lead to secondary prevention by controlling risk factors such as systolic hypertension.
3,962 citations
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
3,870 citations
TL;DR: Higher folic acid intake by reducing tHcy levels promises to prevent arteriosclerotic vascular disease and under different assumptions, 13,500 to 50,000 CAD deaths annually could be avoided.
Abstract: Objective. —To determine the risk of elevated total homocysteine (tHcy) levels for arteriosclerotic vascular disease, estimate the reduction of tHcy by folic acid, and calculate the potential reduction of coronary artery disease (CAD) mortality by increasing folic acid intake. Data Sources. —MEDLINE search for meta-analysis of 27 studies relating homocysteine to arteriosclerotic vascular disease and 11 studies of folic acid effects on tHcy levels. Study Selection and Data Extraction. —Studies dealing with CAD, cerebrovascular disease, and peripheral arterial vascular disease were selected. Three prospective and six population-based case-control studies were considered of high quality. Five cross-sectional and 13 other case-control studies were also included. Causality of tHcy's role in the pathogenesis of vascular disease was inferred because of consistency across studies by different investigators using different methods in different populations. Data Synthesis. —Elevations in tHcy were considered an independent graded risk factor for arteriosclerotic vascular diseases. The odds ratio (OR) for CAD of a 5-μmol/L tHcy increment is 1.6(95% confidence interval [Cl], 1.4 to 1.7) for men and 1.8 (95% Cl, 1.3 to 1.9) for women. A total of 10% of the population's CAD risk appears attributable to tHcy. The OR for cerebrovascular disease (5-μmol/L tHcy increment) is 1.5 (95% Cl, 1.3 to 1.9). Peripheral arterial disease also showed a strong association. Increased folic acid intake (approximately 200 μg/d) reduces tHcy levels by approximately 4 μmol/L. Assuming that lower tHcy levels decrease CAD mortality, we calculated the effect of (1) increased dietary folate, (2) supplementation by tablets, and (3) grain fortification. Under different assumptions, 13 500 to 50 000 CAD deaths annually could be avoided; fortification of food had the largest impact. Conclusions. —A 5-μmol/L tHcy increment elevates CAD risk by as much as cholesterol increases of 0.5 mmol/L (20 mg/dL). Higher folic acid intake by reducing tHcy levels promises to prevent arteriosclerotic vascular disease. Clinical trials are urgently needed. Concerns about masking cobalamin deficiency by folic acid could be lessened by adding 1 mg of cobalamin to folic acid supplements. ( JAMA . 1995;274:1049-1057)
3,722 citations